Company profile
Inyx, Inc.
OTC: IYXI · Healthcare · Medical - Pharmaceuticals
#215 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
——FH —DQ —GM —SS 58
v0.1 · 5/100 weight · pillars only
↑ 3-yr revenue growth, revenue growth (YoY) · ↓ growth stability, market scale
Methodology →Revenue TTM
$531.1M
Rev growth YoY (TTM)
+1781.0%
Net income (FY)
-$31.0M
Employees
572
as of 2026-08-30
Market cap
$5.2k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$495.6M$495.6M2005
Net income-$31.0M-$31.0M2005
Operating income$20.9M$20.9M2005
Total assets$92.2M$92.2M2005
Liabilities$122.6M$122.6M2005
Equity-$30.4M-$30.4M2005
Revenue trend
FY2002 – FY2005 · USD
FY02
FY03
FY04
FY05
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Inyx, Inc.’s revenue?
Inyx, Inc. booked $495.6M in FY2005 revenue, growing 3057% year over year — faster than 98% of Healthcare companies we track, at a -6.3% net margin.
Peers · Healthcare
Oncology Institute, Inc. Warrant 2021-15.11.26 on Oncology Inst59CBridgeBio Pharma, Inc.53DAscend Wellness Holdings, Inc.53DTravere Therapeutics, Inc.74BPhreesia, Inc.68BAyr Wellness Inc.——Neighbors
New York →Key facts
CEOSteven Handley
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersNew York, NY
ExchangeOTC: IYXI
Employees572
IPO date2003-02-19
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.